Comparative Pharmacology
Head-to-head clinical analysis: CLOTIC versus DERMOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOTIC versus DERMOTIC.
CLOTIC vs DERMOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole is an imidazole antifungal that inhibits ergosterol synthesis by inhibiting 14α-demethylase (CYP51), leading to disruption of fungal cell membrane integrity and increased permeability.
Dermotic (fluocinolone acetonide) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid, thereby suppressing the synthesis of prostaglandins and leukotrienes, leading to anti-inflammatory and immunosuppressive effects.
Topical: Apply a thin layer to affected areas 2-4 times daily. Duration limited to 2 weeks; maximum 50 g/week. Intralesional: 0.5-1 mL of 10 mg/mL solution injected into lesion weekly.
Each 1 mL contains 1 mg betamethasone valerate, 10 mg neomycin sulfate, 10,000 units polymyxin B sulfate. Apply 3-4 drops into affected ear(s) 2-3 times daily for 7-10 days.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2.5-4.5 h) in adults with normal renal function; extends to 6-8 hours in mild-moderate renal impairment.
Terminal elimination half-life is 12-18 hours. In patients with renal impairment, half-life may be prolonged; dose adjustment recommended for CrCl <30 mL/min.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as inactive conjugates.
Primarily renal excretion of unchanged drug (approximately 70-80%) with the remainder metabolized and excreted via biliary/fecal routes (20-30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid